Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin.
Poly(alkyl cyanoacrylate) nanocapsules have been successfully used for oral administration of insulin in diabetic rats. This work reports a suitable formulation for insulin-loaded nanospheres composed of full polymeric structures formed by polymerization of isobutyl cyanoacrylate (IBCA) in an acidic medium, insulin (15 U/mL) being added to the polymerization medium 60 min after the onset of polymerization. These nanospheres (MW 364) displayed a mean size of 145 nm and an association rate of 1 U of insulin/mg of polymer. They protected insulin from the degradation by proteolytic enzymes in vitro, especially when they were dispersed in an oily medium (Miglyol 812) containing surfactive agents (Poloxamer 188 and deoxycholic acid). When dispersed in the same medium, insulin-loaded nanospheres (100 U/kg of body weight), administered perorally in streptozotocin-induced diabetic rats, provoked a 50% decrease of fasted glycemia from the second hour up to 10-13 days. This effect was shorter (2 days) or absent when nanospheres were dispersed in water with surfactive agents or not. Using 14C-labeled nanospheres loaded with [125I]insulin, it was found that nanospheres increased the uptake of [125I]insulin or its metabolites in the gastrointestinal tract, blood, and liver while the excretion was delayed when compared to [125I]insulin nonassociated to nanospheres; in addition, 14C- and 125I-radioactivities disappeared progressively as a function of time, parallel to the biological effect. Thus insulin-loaded nanospheres can be considered as a convenient delivery system for oral insulin at the prerequisite that they were dispersed in an oily phase containing surfactants.
Damgé
C
C
Centre Européen d'Etude du Diabète, Strasbourg, France.
Vranckx
H
H
Balschmidt
P
P
Couvreur
P
P
D000284:Administration, Oral; D000818:Animals; D001711:Biotransformation; D001786:Blood Glucose / Q000378:metabolism; D003487:Cyanoacrylates / Q000737:chemistry / Q000493:pharmacokinetics; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism; D004337:Drug Carriers; D004659:Enbucrilate; D010450:Endopeptidases / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D007328:Insulin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D008863:Microspheres; D011108:Polymers / Q000737:chemistry / Q000493:pharmacokinetics; D051381:Rats; D014018:Tissue Distribution
D001786:Blood Glucose; D003487:Cyanoacrylates; D004337:Drug Carriers; D007004:Hypoglycemic Agents; D007328:Insulin; D011108:Polymers; D010450:Endopeptidases; D004659:Enbucrilate